TSE:IN

InMed Pharmaceuticals Stock Forecast, Price & News

C$4.19

-0.07 (-1.64 %)

(As of 05/7/2021)

Add

Compare

Today's Range

C$4.13

▼

C$4.27

50-Day Range

C$3.46

▼

C$4.82

52-Week Range

C$3.35

▼

C$13.70

Volume17,035 shs

Average Volume29,552 shs

Market CapitalizationC$33.73 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive IN News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
May 13, 2021 | finance.yahoo.com

InMed Pharmaceuticals Inc Registered Shs hosts conference call for investors
May 12, 2021 | markets.businessinsider.com

InMed Pharmaceuticals (IN) Scheduled to Post Quarterly Earnings on Thursday
May 7, 2021 | americanbankingnews.com

InMed Pharmaceuticals (IN) Set to Announce Quarterly Earnings on Thursday
May 7, 2021 | americanbankingnews.com

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
May 6, 2021 | finance.yahoo.com

BRIEF-Inmed Pharmaceuticals Submits Clinical Trial Applications To Evaluate INM-755 Cream In Phase 2 Trial For Epidermolysis Bullosa
April 28, 2021 | msn.com

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 28, 2021 | finance.yahoo.com

InMed to Present at Virtual Conferences in March 2021
March 3, 2021 | finance.yahoo.com

InMed Announces US$4.5 Million Private Placement
February 5, 2021 | finance.yahoo.com

IIROC Trading Halt - IN
February 5, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:IN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.inmedpharma.com

Phone604-669-7207

Employees4

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowC$1.43 per share

Price / Cash Flow2.93

Book ValueC$1.08 per share

Price / Book3.87

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity Ratio4.15

Current Ratio4.76

Quick Ratio4.73

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares8,050,710

Market CapC$33.73 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.64 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for InMed Pharmaceuticals.

3.2 Community Rank

Outperform Votes
InMed Pharmaceuticals has received 7 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
InMed Pharmaceuticals has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
InMed Pharmaceuticals has received 63.64% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about InMed Pharmaceuticals and other stocks. Vote “Outperform” if you believe IN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
InMed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
InMed Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of InMed Pharmaceuticals is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InMed Pharmaceuticals is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InMed Pharmaceuticals has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

InMed Pharmaceuticals (TSE:IN) Frequently Asked Questions

What stocks does MarketBeat like better than InMed Pharmaceuticals?

Wall Street analysts have given InMed Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has InMed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

InMed Pharmaceuticals' stock was trading at C$0.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IN stock has increased by 1,576.0% and is now trading at C$4.19.
View which stocks have been most impacted by COVID-19.

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:

Mr. Eric A. Adams, Pres, CEO & Director (Age 57, Pay $423.76k)
Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 56, Pay $313.13k)
Ms. Alexandra Diane-Janet Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 68, Pay $308.19k)
Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 51, Pay $300.7k)
Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 54, Pay $287.6k)
Dr. Sazzad Hossain, Co-Founder
Mr. Brendan Payne, Director of Investor Relations
Mr. Richard Hoy, VP of Sales & Marketing
Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

Who are some of InMed Pharmaceuticals' key competitors?

Some companies that are related to InMed Pharmaceuticals include Shield Therapeutics (STX), Venture Life Group (VLG), Science in Sport (SIS), WeedMD (WMD), Diurnal Group (DNL), Delta 9 Cannabis (NINE), The Flowr (FLWR), Acerus Pharmaceuticals (ASP), BioSyent (RX), Cipher Pharmaceuticals (CPH), Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Indiva (NDVA) and Harvest One Cannabis (HVT).
View all of IN's competitors.

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?

Shares of IN and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is InMed Pharmaceuticals' stock price today?

One share of IN stock can currently be purchased for approximately C$4.19.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals has a market capitalization of C$33.73 million.

How many employees does InMed Pharmaceuticals have?

InMed Pharmaceuticals employs 4 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207.

This page was last updated on 5/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

InMed Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding InMed Pharmaceuticals Inc.

About InMed Pharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

3.2 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth

0.0 Company Ownership

Insider Buying vs. Insider Selling